Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) VP Michael S. Aberman sold 3,611 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $350.00, for a total transaction of $1,263,850.00. Following the transaction, the vice president now directly owns 15,600 shares of the company’s stock, valued at approximately $5,460,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.55% during mid-day trading on Thursday, hitting $343.37. 125,729 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $233.06 and a one year high of $353.05. The stock’s 50-day moving average is $321.5 and its 200-day moving average is $310.0. The company has a market cap of $34.471 billion and a price-to-earnings ratio of 98.26.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.15 EPS for the current fiscal year.

REGN has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $345.94.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.